Alain Bauza, MD
Ophthalmology · Freehold, NJNPI 1619234077
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Biotissue Holdings Inc. accounts for 79.9% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $40,539, more than ten times the $1,399 reported in 2019. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 300 payments — averaging $193.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$46K
- Tarsus Pharmaceuticals, Inc.$4K
- Bausch & Lomb Americas Inc.$4K
- AbbVie$707
- Johnson & Johnson Surgical Vision, Inc.$500
- Sight Sciences, Inc.$357
- plus $2K from 17 others
What the payments were for
- Consulting fees$32,90057%
- Speaking & faculty fees$9,16916%
- Travel & lodging$7,75113%
- Food & beverage$8,04514%
- Education$1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 92 | $46,351 |
| Tarsus Pharmaceuticals, Inc. | 29 | $4,256 |
| Bausch & Lomb Americas Inc. | 42 | $4,189 |
| AbbVie(2 entities) | 36 | $707 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $500 |
| Sight Sciences, Inc. | 6 | $357 |
| Alcon | 15 | $283 |
| Sun Pharmaceutical Industries Inc. | 14 | $226 |
| Novartis | 17 | $208 |
| Glaukos Corporation | 2 | $193 |
| Harrow Eye, LLC | 5 | $171 |
| Dompe US, Inc. | 7 | $123 |
| Ocular Therapeutix, Inc. | 4 | $80 |
| Kala Pharmaceuticals, Inc. | 5 | $74 |
| Aerie Pharmaceuticals, Inc. | 4 | $58 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $44 |
| Shire North American Group Inc | 3 | $39 |
| NEW World Medical,inc. | 1 | $27 |
| LKC Technologies, Inc. | 1 | $27 |
| Oyster Point Pharma, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Johnson & Johnson Vision Care, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$40,518
- MIEBO$3,371
- XIIDRA$3,371
- AmnioGraft$2,546
- XDEMVY$1,500
- AmnioGuard$809
- OMNI(R) SURGICAL SYSTEM (US)$278
- enVista MX60 IOL$250
- Tecnis IOL$247
- iDoseTR$169
- STELLARIS$149
- CATALYS SYSTEM$123
- RESTASIS MULTIDOSE$117
- DURYSTA$113
- VEVYE$102
How this compares
$57,978 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 73 | $117,732 |
| ProlensaBromfenac Sodium | 189 | $65,250 |
| RestasisCyclosporine | 53 | $56,489 |
| XdemvyLotilaner | 26 | $49,459 |
| LumiganBimatoprost | 55 | $20,749 |
| Prednisolone Acetate | 618 | $20,373 |
| Cyclosporine | 28 | $16,289 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 54 | $13,818 |
| MieboPerfluorohexyloctane/Pf | 14 | $13,009 |
| MoxifloxacinMoxifloxacin Hcl | 521 | $12,922 |
| Bromfenac Sodium | 39 | $7,797 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $6,271 |
| Fluorometholone | 67 | $6,092 |
| VyzultaLatanoprostene Bunod | 17 | $5,762 |
| Ketorolac Tromethamine | 263 | $4,455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $4,189 | $136,503104 claims |
| AbbVieRestasis, Lumigan | $707 | $77,238108 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $44 | $69,525206 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $4,256 | $49,45926 claims |
| AlconSimbrinza | $283 | $13,81854 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $58 | $6,27111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Freehold
- Rajen DesaiFreehold$311K
- Eric GershenbaumFreehold$23K
- Revathi NaadimuthuFreehold$12K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.